Ceapro Inc V.CZO

Biotech

[prophetoffactz]

@buysidebio

 

Worst Biotech Bear Market On Record The Sub 200M market cap bracket has seen the largest decline since 2/8/21, with an average drop of -86% and a median of -93%. Companies in the 200M-500M range lost over half their value since the peak, with a median decline of -79%. Larger companies, specifically those with a market cap of 8B+, showed resilience with an average return of 11% year-to-date and an increase of 9% since the 2/8/21 peak. Across all market cap buckets, there's been an average decline of -43% since 2/8/21, with a median drop of -54%. The number of companies with a negative enterprise value (EV) surged from 6 on 2/8/21 to 221 (35%) currently. Remarkably, 71% of these negative EV companies have less than 2 years of cash. 20% of biotech companies previously bucketed back on 2/8/21 are now valued at <50M. $XBI

[Apostata]

We're not even in the same area code as the $XBI. Below is a one-year comparison between XBI, CZO and AEZS:

[prophetoffactz]

Read what sub $200 million market cap companies have done below. CZO also has a unique situation where a client representing half its base business may have disappeared but will be back.  @buysidebio